Edwards Lifesciences Corp (EW)vsNovocure Ltd (NVCR)
EW
Edwards Lifesciences Corp
$84.37
-2.77%
HEALTHCARE · Cap: $49.99B
NVCR
Novocure Ltd
$15.51
+1.04%
HEALTHCARE · Cap: $2.09B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 831% more annual revenue ($6.51B vs $699.19M). EW leads profitability with a 15.4% profit margin vs -21.2%. EW earns a higher WallStSmart Score of 55/100 (C).
EW
Buy55
out of 100
Grade: C
NVCR
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.9%
Fair Value
$254.99
Current Price
$84.37
$170.62 discount
Margin of Safety
+81.5%
Fair Value
$56.59
Current Price
$15.51
$41.08 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Strong operational efficiency at 29.8%
15.6% revenue growth
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 25.4%
Weak financial health signals
ROE of -52.3% — below average capital efficiency
Earnings declined 6.0%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Debt/Equity, Altman Z-Score, Operating Margin. Profitability is solid with margins at 15.4% and operating margin at 29.8%. Revenue growth of 13.6% demonstrates continued momentum.
Bull Case : NVCR
The strongest argument for NVCR centers on Revenue Growth. Revenue growth of 15.6% demonstrates continued momentum.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 51.6x leaves little room for execution misses.
Bear Case : NVCR
The primary concerns for NVCR are Piotroski F-Score, Return on Equity, EPS Growth.
Key Dynamics to Monitor
EW profiles as a mature stock while NVCR is a growth play — different risk/reward profiles.
NVCR carries more volatility with a beta of 1.01 — expect wider price swings.
NVCR is growing revenue faster at 15.6% — sustainability is the question.
EW generates stronger free cash flow (585M), providing more financial flexibility.
Bottom Line
EW scores higher overall (55/100 vs 29/100), backed by strong 15.4% margins and 13.6% revenue growth. NVCR offers better value entry with a 81.5% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Novocure Ltd
HEALTHCARE · MEDICAL DEVICES · USA
NovoCure Limited, an oncology company, is engaged in the development, manufacture and marketing of Optune for the treatment of a variety of solid tumors. The company is headquartered in Saint Helier, Jersey.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?